Thank you for submitting your manuscript to the EMBO Journal. I have now received the comments from the three referees that I have provided below. I am sorry for the delay in getting back to you with a decision, but I think you will be pleased with the outcome. As you can see from the comments below, the three referees are very enthusiastic about your analysis. They find the analysis makes an important contribution to the field. They raise a number of concerns that shouldn't involve too much additional work to resolve. The text in particular needs to be streamlined and made more succinct.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
------------------------------------------------REFEREE REPORTS
Referee #1:
This manuscript reports structures of complement protein C3b in complex with four ligands: three members of the regulators of complement activation (RCA) family (MCP, DAF and CR1), as well as one viral activator (SPICE). Structures of C3b alone (at lower resolution) and of a complex of C3b with the RCA member Factor H (FH) had been determined earlier, and structures of various regions of isolated activators MCP, DAF, FH and CR1 were also known prior to this work. The data presented in this paper are clearly of interest to the scientific community as the new structures provide a framework for understanding the nature of the interactions of C3b with a range of activators as well as mutations observed in a range of diseases.
The structural analyses reveal a complicated binding mode in which the different ligands bind in an elongated conformation to the same surface area of C3b, but using different interactions and domains.
The structures have different resolutions (ranging from 2.4 to 4.2 Å) but they all have adequate statistics.
Comments:
-These are large complexes with many features, but I still feel that the manuscript does not really do a good job describing them, at least to readers who are not experts on complement protein structures. The writing is quite dense, and often seems not well structured. Subheadings in the Results & Discussion section would help guide the reader, and so would adding labels of CCP domains etc to some of the figures.
-There is some speculation about evolution towards the end of the manuscript, and I did not find the arguments very compelling. For example, the authors state that DAF and CD46 bind C3b similarly (page 14 top), and that they thus might have evolved from a common C3b-binding mechanism. Maybe so, but the binding modes of these two proteins are not really so similar, DAF binds with three domains, MCP with two, and only one of these domains overlaps (DAF CCP4 with MCP CCP3). Moreover, Table 2 shows rather different binding surface areas for these two domains (843 Å2 and 443 Å2, respectively).
- Table 2 , and text: The resolution of the C3b/CR1 complex (3.3Å) is probably just good enough for a detailed analysis of contacts, but the C3b/DAF complex has a resolution of only 4.2 Å, and I wonder how precisely contacts between amino acid side chains can really be assigned at this resolution? Maybe the analysis of this latter complex should just be limited to the buried surface area in this table. I don't think it makes sense to discuss specific contacting amino acids and count ionic interactions etc here.
- Table 1 : A redundancy-independent R-factor (such as Rmeas) should be used instead of Rsym. Also it would help here if individual B-factors could be listed for C3b and for the various CCP domains in each complex.
-I found it very interesting that the four ligands apparently have evolved somewhat different mechanisms of binding to the same surface of C3b. The authors speculate about how this could be explained in terms of evolution, but it seems it is also possible that the binding surface of C3b is for some reason best suited to bind ligands (perhaps because other regions do other things, such as mediating conformational changes). Thus convergent evolution should also be considered I think.
-The CCP domain proteins (MCP, DAF, FH etc) are described as being flexibly linked, which is true for some linkages but not for others. The interface between CCP3 and CCP4 in MCP is for example less flexible.
-Most of Figure 4 depicts FH/C3b interactions and locations of mutants on FH. However, the C3b/FH complex structure is not part of this manuscript, and a generally similar figure was shown in the manuscript reporting that structure in 2009 (Wu et al, Nat Immunol).
-One of the citations on the host recognition molecules that serve FH is poorly chosen, namely Ormsby et al 2006 -the 'third' GAG binding site in FH claimed by this article was later shown to be a cloning artifact (see Schmidt et al., J. Immunol 2008). The most comprehensive article on GAGrecognition by FH to date is probably Clark SJ et al, J. Immunol. 2013, and this article would be a much better choice to cite here. At the same location in the manuscript the phrase 'such as glycosaminoglycans' could be changed to 'such as glycosaminoglycans and sialic acid' since both sugars markers are now thought to differentially protect different tissue from complement, as pointed out by the work of Simon Clark and the cited article by Blaum et al, 2015.
-The observation of a 100{degree sign} rotation of CCP4 in FH vs MCP and SPICE is a little difficult to follow. 100 {degree sign} with respect to what? With respect to the orientation that FH CCP4 adopts when superposed as a single domain with the single domains MCP CCP4 and SPICE CCP4? Another cartoon in Fig. 3B , i.e. a superposition of FH CCP3-4, SPICE CCP3-4, and MCP CCP3-4 based on CCP4 instead of their bound C3b partners could help to clarify this interesting observation.
-'Footprint' in legend to Fig. 2 . Based on the SPICE-C3b structure it appears likely that also CCP1-2 of VCP contacts C3b in the VCP-C3b complex and thus it is puzzling that the full-length VCP structure is not used here. Is this choice a precautionary measure due to the controversy that surrounds the fake C3b structure by Krishna et al., or was the VCP CCP1-4 crystal structure 1G40.pdb evaluated for the current manuscript and found not to be trustworthy? If this is the case it would be noteworthy to state this observation in the current manuscript since the pdb in question and the associated article in Cell are currently not withdrawn or flagged as controversial and the complement community would benefit from the authors' expert opinion on the subject, if based on careful evaluation.
-Some of the SPR titrations were stopped before saturation was reached, particularly visible for SPICE and FH. The fitted curves and Kd-values are therefore questionable.
Minor comments: -The concept of a 'MiniFH' consisting of FH CCP 1-4 plus CCP 19-20 is mentioned in the introduction, and the paper by Schmidt and co-workers is correctly cited. Since Mihaly Jόzsi came up with essentially the same idea at the same time, it would probably be fair to also cite his work here (Hebecker M. et al. 2013 ).
-Usage of the Kd abbrevation is inconsistent. -Several abbreviations are used but not explained or not explained where they are first used (DDD, NCS, VCP). -The treatment used to remove N-linked glycans from CR1 is not described in the Methods section.
Referee #2:
The complement system is a critical element of the first-line defences against infection and is tightly regulated by a series of membrane bound and serum-resident proteins. In this work one class of complement regulatory protein mechanisms is dissected in detail in a series of landmark structures. The conclusions drawn are supported by reinterpretation of much earlier literature to give a definitive interpretation of mechanisms of regulation of C3b activity. The manuscript is clearly suitable for publication in EMBO Journal and should be of interest to many different communities.
This manuscript reports multiple structures of the large complex between complement C3b and members of the regulators of complement activity family. In so-doing it brings together and explains much previous data providing a clear structural framework for understanding both decay accelerating and co-factor complement regulatory activity. The experiments are definitive and clearly described.
One minor point -on page 10 a two domain structure of DAF is incorrectly cited as being of domains 1 and 2 -it is in fact of domains 3 and 4.
Referee #3:
Forneris et al. present new structures on three important negative regulators of complement activation (RCA): DAF, MCP and CR1. In addition, they describe the structure of a smallpox virus homologue, SPICE, in complex with C3b. All four regulators inactivate complement through decay of complement convertases as well as through co-factor activity towards factor I, an important soluble regulator of complement activation. Binding of the RCA proteins and SPICE to C3b is established through conserved repetitive protein domains consisting of 60-70 amino acid, also called "CCP" repeats. Based on the co-structures of these negative regulators with C3b, the authors conclude that the structural requirements for co-factor or decay-accelerating activity vary among the RCA proteins. However, the binding interface on C3b is conserved among these negative regulators, classifying the C3b-regulator binding as extensive variations on a common binding mode. The structure of SPICE, which is not a RCA proteins but a viral protein evolved by molecular mimicry of RCA proteins, further explains how the conserved C3b binding mode can be exploited by viruses to evade complement attack.
The authors present new insights on how RCA proteins function at the molecular level. This is an important contribution to the field for several reasons: 1) The structures, that enable mapping of the RCA binding interface with C3b can now explain the functional consequences of several diseasecausing genetic polymorphisms in RCA proteins and in C3b, 2) the structures could guide the development of therapeutics for the treatment of complement-mediated diseases, and 3) they explain the molecular basis of complement evasion by some viruses.
My major comment is that the paper could be more succinct and focused on the major conclusions of the study. This prevents the main message of this well performed and data-rich study from getting lost. The first part of the Introduction is too general and could be shortened by referring to excellent complement review papers published by the authors. The Results section could be more succinct, and the conclusions more focused on the most important findings in the paper.
More specific comments: -The structure of SPICE-C3b is important as it can demonstrate how molecular mimicry may impact infection and immunity. This message is getting lost in the abstract, results and discussion section. "Host protection" mentioned at numerous places in the text refers to RCA proteins and not SPICE -that has evolutionary evolved to help the virus infect the host. This needs more clarification in the text, in particular in the Abstract.
- Figure 4 : C3 protein, used to generate the 2.8 A C3b structure, was purified from pooled human plasma. It would be informative to know if any of the disease-causing variants in C3b, depicted in Figure 4A and B, are present in the crystallized C3b protein. Response to Referees
-These are large complexes with many features, but I still feel that the manuscript does not really do a good job describing them, at least to readers who are not experts on complement protein structures. The writing is quite dense, and often seems not well structured. Subheadings in the Results & Discussion section would help guide the reader, and so would adding labels of CCP domains etc to some of the figures. Figure 1B , 4B/C and S4F of the Appendix.
Reply 1.2 We have strengthened the argument on page 14. Having both dual-activity regulators (like FH and SPICE with both decay-accelerating and cofactor activity) and single-activity regulators [decayaccelerating DAF and cofactor activity MCP and CR1 (CCP15-17)
] makes a common origin with divergent evolution a simpler and therefore a more favorable model than convergent evolution.
- Table 2 , and text: The resolution of the C3b/CR1 complex (3.3Å) is probably just good enough for a detailed analysis of contacts, but the C3b/DAF complex has a resolution of only 4.2 Å, and I wonder how precisely contacts between amino acid side chains can really be assigned at this resolution? Maybe the analysis of this latter complex should just be limited to the buried surface area in this table. I don't think it makes sense to discuss specific contacting amino acids and count ionic interactions etc here. -Most of Figure 4 depicts FH/C3b interactions and locations of mutants on FH. However, the C3b/FH complex structure is not part of this manuscript, and a generally similar figure was shown in the manuscript reporting that structure in 2009 (Wu et al, Nat Immunol).
Reply 1.7
In the four panels displayed in Figure 4, Fig. 3B , i.e. a superposition of FH CCP3-4, SPICE CCP3-4, and MCP CCP3-4 based on CCP4 instead of their bound C3b partners could help to clarify this interesting observation. Fig. S4A . Fig 3A and Fig 3B for clarification.
Reply 1.9 Superposing of FH-CCP4 and MCP-CCP4 yields a rotation of ~100° around the longitudinal axis of the domain, as given in the manuscript. Superpositions of FH CCP3-4, SPICE CCP3-4 and MCP CCP3-4 are part of the data shown in

B reflect how this difference affects the overall complex, yielding completely different interactions faces but an identical overall arrangement of the complex. To address the reviewer's concern, we added the axis of rotation to
-'Footprint' in legend to Fig. 2 warrants an explanation.
Reply 1.10
We modified Figure 2A to clarify the concept of "footprint" used in Fig. 2 , and changed the figure legend accordingly. . Based on the SPICE-C3b structure it appears likely that also CCP1-2 of VCP contacts C3b in the VCP-C3b complex and thus it is puzzling that the full-length VCP structure is not used here. Is this choice a precautionary measure due to the controversy that surrounds the fake C3b structure by Krishna et al., or was the VCP CCP1-4 crystal structure 1G40.pdb evaluated for the current manuscript and found not to be trustworthy? If this is the case it would be noteworthy to state this observation in the current manuscript since the pdb in question and the associated article in Cell are currently not withdrawn or flagged as controversial and the complement community would benefit from the authors' expert opinion on the subject, if based on careful evaluation. Minor comments: -The concept of a 'MiniFH' consisting of FH CCP 1-4 plus CCP 19-20 is mentioned in the introduction, and the paper by Schmidt and co-workers is correctly cited. Since Mihaly Jόzsi came up with essentially the same idea at the same time, it would probably be fair to also cite his work here (Hebecker M. et al. 2013).
Reply 1.14 This citation has been included into the manuscript.
-Usage of the Kd abbrevation is inconsistent.
Reply 1.15
All occurrences modified to K D .
-Several abbreviations are used but not explained or not explained where they are first used (DDD, NCS, VCP).
Reply 1.16
Abbreviation VCP defined at first use. DDD is replaced by C3G. NCS abbreviation deleted.
-The treatment used to remove N-linked glycans from CR1 is not described in the Methods section.
Reply 1.17
The remark concerning deglycosylation of CR1 CCP15-17 was incorrect and has been deleted. The material was produced as described in the given reference.
Referee #2:
Reply 2.1 Corrected in the manuscript.
Referee #3:
Forneris et al. present new structures on three important negative regulators of complement activation (RCA): DAF, MCP and CR1. In addition, they describe the structure of a smallpox virus homologue, SPICE, in complex with C3b. All four regulators inactivate complement through decay of complement convertases as well as through co-factor activity towards factor I, an important soluble regulator of complement activation. Binding of the RCA proteins and SPICE to C3b is established through conserved repetitive protein domains consisting of 60-70 amino acid, also called "CCP" repeats. Based on the co-structures of these negative regulators with C3b, the authors conclude that the structural requirements for co-factor or decay-accelerating activity vary among the RCA proteins. However, the binding interface on C3b is conserved among these negative regulators, classifying the C3b-regulator binding as extensive variations on a common binding mode. The structure of SPICE, which is not a RCA protein[s] but a viral protein evolved by molecular mimicry of RCA proteins, further explains how the conserved C3b binding mode can be exploited by viruses to evade complement attack.
Reply 3.1 We have shortened the introduction, results and discussion sections by focusing on the major issues. We feel this has improved readability and we thank the reviewer for her/his comments.
More specific comments: -The structure of SPICE-C3b is important as it can demonstrate how molecular mimicry may impact infection and immunity. This message is getting lost in the abstract, results and discussion section. "Host protection" mentioned at numerous places in the text refers to RCA proteins and not SPICE -that has evolutionary evolved to help the virus infect the host. This needs more clarification in the text, in particular in the Abstract. - Figure 4 : C3 protein, used to generate the 2.8 A C3b structure, was purified from pooled human plasma. It would be informative to know if any of the disease-causing variants in C3b, depicted in Figure 4A and B, are present in the crystallized C3b protein. Thank you for submitting the revised manuscript. I have now had a chance to take a look at it and I appreciate the introduced changes. I am therefore very pleased to accept the manuscript for publication here. Is there an estimate of variation within each group of data?
Is the variance similar between the groups that are being statistically compared? 6. To show that antibodies were profiled for use in the system under study (assay and species), provide a citation, catalog number and/or clone number, supplementary information or reference to an antibody validation profile. e.g., Antibodypedia (see link list at top right), 1DegreeBio (see link list at top right).
7. Identify the source of cell lines and report if they were recently authenticated (e.g., by STR profiling) and tested for mycoplasma contamination. 
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation. a statement of how many times the experiment shown was independently replicated in the laboratory.
Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
Please ensure that the answers to the following questions are reported in the manuscript itself. We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects. Coordinates and structure factors for C3b and the complexes of C3b--MCP (CCP1--4), C3b--CR1 (CCP15--17), C3b--DAF (CCP2--4) and C3b--SPICE (CCP1--4) have been deposited at the Protein Data Bank (PDB) with accession numbers 5FO7, 5FO8, 5FO9, 5FOA and 5FOB, respectively. Raw diffraction images will be made available through the "data repository" section of our research group website, http://www. The fresh human plasma used for the purification of C3 (see Materials and Methods) was obtained from an informed healthy donor.
F--Data Accessibility
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